Relief Therapeutics Holding SA
SIX:RLF

Watchlist Manager
Relief Therapeutics Holding SA Logo
Relief Therapeutics Holding SA
SIX:RLF
Watchlist
Price: 1.06 CHF -63.26% Market Closed
Market Cap: 437m CHF

Operating Margin

-484.4%
Current
Declining
by 189.9%
vs 3-y average of -294.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-484.4%
=
Operating Income
CHf-19.6m
/
Revenue
CHf4.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-484.4%
=
Operating Income
CHf-19.6m
/
Revenue
CHf4.1m

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Relief Therapeutics Holding SA
SIX:RLF
437m CHF
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
377.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
156.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 96% of companies in Switzerland
Percentile
4rd
Based on 1 083 companies
4rd percentile
-484.4%
Low
-62 472.2% — 3.5%
Typical Range
3.5% — 16.5%
High
16.5% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 3.5%
Median 10.3%
70th Percentile 16.5%
Max 91.2%

Relief Therapeutics Holding SA
Glance View

Market Cap
437m CHF
Industry
Biotechnology

RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

RLF Intrinsic Value
0.09 CHF
Overvaluation 91%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-484.4%
=
Operating Income
CHf-19.6m
/
Revenue
CHf4.1m
What is Relief Therapeutics Holding SA's current Operating Margin?

The current Operating Margin for Relief Therapeutics Holding SA is -484.4%, which is below its 3-year median of -294.5%.

How has Operating Margin changed over time?

Over the last 3 years, Relief Therapeutics Holding SA’s Operating Margin has increased from -586.3% to -484.4%. During this period, it reached a low of -586.3% on May 30, 2022 and a high of -88.5% on Dec 31, 2024.

Back to Top